Peter N. Morcos - Concepedia

Author

Peter N. Morcos

Roche (Switzerland)ORCID

Also Known As

P. Morcos, P.N. Morcos, Peter Morcos, Peter N Morcos, Peter N. Morcos

Publications

1.5K

Citations

H-Index

Concepts

All Affiliations

Roche (Switzerland)La Roche College Roche (United Kingdom)Institut Català d'Oncologia Vall d'Hebron Hospital Universitari

About

Peter N. Morcos is an author at Roche (Switzerland) specializing in medicine, virology, and biomolecular engineering.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	390
2	Biomolecular Engineering	2	2	32
3	Public Health	1	1	23
4	Biochemistry	1	1	13
5	Hepatology	1	1	335

Peter N. Morcos

Publications

1.3K

Citations

H-Index

Page 1

	Year	Citations
Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell–Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial Martin Hutchings, Franck Morschhauser, Gloria Iacoboni, Journal of Clinical Oncology	2021	392
Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial Edward Gane, Stuart K. Roberts, Catherine AM Stedman, The Lancet HepatologyHepatitis CViral HepatitisAntiviral TherapyHepatitis	2010	335
Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy Christina Claus, Claudia Ferrara, Wei Xu, Science Translational Medicine	2019	252
Pharmacokinetic/Pharmacodynamic Predictors of Clinical Potency for Hepatitis C Virus Nonnucleoside Polymerase and Protease Inhibitors Micaela B. Reddy, Peter N. Morcos, Sophie Le Pogam, Antimicrobial Agents and Chemotherapy	2012	43
CD20-Tcb (RG6026), a Novel "2:1" Format T-Cell-Engaging Bispecific Antibody, Induces Complete Remissions in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma: Preliminary Results from a Phase I First in Human Trial Martin Hutchings, Gloria Iacoboni, Franck Morschhauser, Blood	2018	32
Bioanalysis of Alectinib and Metabolite M4 in Human Plasma, Cross-Validation and Impact on PK Assessment Katja Heinig, Kazuhiro Miya, Tomonori Kamei, Bioanalysis	2016	28
CD20-TCB, a Novel T-Cell-Engaging Bispecific Antibody, Can be Safely Combined with the Anti-PD-L1 Antibody Atezolizumab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma Martin Hutchings, Giuseppe Gritti, Anna Sureda, Blood	2019	28
Dual CD20-Targeted Therapy With Concurrent CD20-TCB and Obinutuzumab Shows Highly Promising Clinical Activity and Manageable Safety in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: Preliminary Results From a Phase Ib Trial Franck Morschhauser, Carmelo Carlo‐Stella, Fritz Offner, Blood	2019	28
Pharmacokinetics and pharmacodynamics of single subcutaneous doses of tocilizumab administered with or without rHuPH20 Peter N. Morcos, Xiaoping Zhang, Christine McIntyre, International Journal of Clinical Pharmacology and Therapeutics	2013	23
Safety, Tolerability, and Pharmacokinetics of Intravenous Oseltamivir: Single- and Multiple-Dose Phase I Studies with Healthy Volunteers Barbara J. Brennan, Brian E. Davies, Georgina Cirrincione‐Dall, Antimicrobial Agents and Chemotherapy	2012	23

Page 1